Towards the development of an effective treatment for SCN1A-derived epilepsy

项目总结 电压门控钠通道SCN1A(编码Nav1.1)的从头功能丧失突变是 德雷特综合征(DS)的主要原因，这是一种灾难性的早期脑病，与长期和 复发性热性癫痫(FSS)、难治性无热性癫痫、认知和行为障碍以及 死亡率为15%-20%。SCN1A突变也会导致遗传性癫痫伴热性惊厥(GEFS+)，以及 以早期FSS和多种成人癫痫的发展为特征的遗传性疾病 子类型。目前的抗癫痫药物往往不能提供足够的保护，防止严重的癫痫发作和 发生在SCN1A突变患者中的神经精神共病。此外，几乎三分之一的人 癫痫患者没有实现足够的癫痫发作控制，突出了发展多模式的迫切需要 可有效缓解与难治性疾病相关的广泛临床特征的治疗方法 癫痫，同时将不良副作用降至最低。在这个探索性的R21提案中，我们将检验假设 石杉碱甲(Hup A)是一种天然的倍半萜石杉碱类生物碱，对糖尿病有明显的治疗作用。 DS的治疗。这一假设是基于Hup A的生物学特性，它证明了它的临床应用 安全性、耐受性、改善认知功能的能力，以及我们的初步数据。我们将使用杂合子 SCN1A基因敲除小鼠(DS模型)评估Hup A提高癫痫阈值和 预防自发性癫痫发作(目标1)和改善认知和行为缺陷(目标2)。 这一具有临床相关性的建议可能为开发一种新的治疗方法奠定基础。 SCN1A型癫痫。此外，由于SCN1A突变导致神经元抑制减少，这是 许多常见形式癫痫的共同机制，这项研究的结果可能有 对于难治性癫痫的治疗具有重要而广泛的意义。

PROJECT SUMMARY De novo loss-of-function mutations in the voltage-gated sodium channel SCN1A (encoding Nav1.1) are the main cause of Dravet syndrome (DS), a catastrophic early-life encephalopathy associated with prolonged and recurrent febrile seizures (FSs), treatment-resistant afebrile epilepsy, cognitive and behavioral deficits, and a 15-20% mortality rate. SCN1A mutations also lead to genetic epilepsy with febrile seizures plus (GEFS+), an inherited disorder characterized by early-life FSs and the development of a wide range of adult epilepsy subtypes. Current anti-epilepsy drugs often fail to provide adequate protection against the severe seizures and neuropsychiatric comorbidities that occur in patients with SCN1A mutations. Furthermore, almost a third of all epilepsy patients do not achieve adequate seizure control, highlighting the urgent need to develop multimodal treatments that can effectively mitigate the broad spectrum of clinical features associated with refractory epilepsies, while minimizing unwanted side effects. In this exploratory R21 proposal, we will test the hypothesis that Huperzine A (Hup A), a naturally occurring sesquiterpene Lycopodium alkaloid, will be efficacious in the treatment of DS. This hypothesis is based on the biological properties of Hup A, its demonstrated clinical safety, tolerability, ability to improve cognitive function, and our preliminary data. We will use heterozygous Scn1a knockout mice (a model of DS) to evaluate the potential of Hup A to increase seizure thresholds and prevent spontaneous seizure generation (Aim 1) and to ameliorate cognitive and behavioral deficits (Aim 2). This clinically relevant proposal could lay the foundation for the development of a novel therapy to treat SCN1A-derived epilepsies. Furthermore, since SCN1A mutations lead to reduced neuronal inhibition, which is a shared mechanism underlying many common forms of epilepsy, the outcome of this study may have important, broad implications for the treatment of refractory epilepsies.